Microwave Ablation, Radiofrequency Ablation, Irreversible Electroporation, and Stereotactic Ablative Body Radiotherapy for Intermediate Size (3–5 cm) Unresectable Colorectal Liver Metastases: a Systematic Review and Meta-analysis

Sanne Nieuwenhuizen1 · Madelon Dijkstra1 · Robbert S. Puijk1 · Bart Geboers1 · Alette H. Ruarus1 · Evelien A. Schouten1 · Karin Nielsen2 · Jan J. de Vries1 · Anna M. E. Bruynzeel3 · Hester J. Scheffer1 · M. Petrousjka van den Tol4 · Cornelis J. A. Haasbeek3 · Martijn R. Meijerink1

Accepted: 6 February 2022 / Published online: 17 March 2022 © The Author(s) 2022

Abstract
Purpose of Review Based on good local control rates and an excellent safety profile, guidelines consider thermal ablation the gold standard to eliminate small unresectable colorectal liver metastases (CRLM). However, efficacy decreases exponentially with increasing tumour size. The preferred treatment for intermediate-size unresectable CRLM remains uncertain. This systematic review and meta-analysis compare safety and efficacy of local ablative treatments for unresectable intermediate-size CRLM (3–5 cm).

Recent Findings We systematically searched for publications reporting treatment outcomes of unresectable intermediate-size CRLM treated with thermal ablation, irreversible electroporation (IRE) or stereotactic ablative body-radiotherapy (SABR). No comparative studies or randomized trials were found. Literature to assess effectiveness was limited and there was substantial heterogeneity in outcomes and study populations. Per-patient local control ranged 22–90% for all techniques; 22–89% (8 series) for thermal ablation, 44% (1 series) for IRE, and 67–90% (1 series) for SABR depending on radiation dose.

Summary Focal ablative therapy is safe and can induce long-term disease control, even for intermediate-size CRLM. Although SABR and tumour-bracketing techniques such as IRE are suggested to be less susceptible to size, evidence to support any claims of superiority of one technique over the other is unsubstantiated by the available evidence. Future prospective comparative studies should address local-tumour-progression-free-survival, local control rate, overall survival, adverse events, and quality-of-life.

Keywords Thermal ablation · Microwave ablation (MWA) · Radiofrequency ablation (RFA) · Irreversible electroporation (IRE) · Stereotactic ablative body radiotherapy (SABR) · Colorectal liver metastases (CRLM)

Introduction
Colorectal cancer (CRC) is one of the most common cancers worldwide and the second leading cause of cancer-related mortality, with almost 1.850.000 new cases worldwide and 881.000 deaths in 2018 [1]. Colorectal liver metastases (CRLM) will develop in 25–30% of these patients during the course of their disease and is the main cause of death in CRC patients [2–5]. When left untreated, the 5-year overall survival (OS) rate is dismal, with survival rates around 0–3% [6–8]. Although systemic therapy alone clearly improves survival, the only treatments that
can provide long-term disease control or in a subset of patients even cure, are local eradication of the tumour.

Following resection of CRLM, 5-year survival rates of 40–55% can be achieved [3–5, 9–12]. Unfortunately, only 20–30% of patients are considered eligible for partial hepatectomy [3, 4, 13]. Induction chemotherapy can downstage another 10–30% to resectable disease [13–16]. Although generally accepted guidelines are lacking, unresectability of CRLM can be roughly defined as follows: (1) an insufficient volume and function of the future liver remnant after resection, (2) inability to spare the arterial or portal venous blood supply to or the venous or biliary drainage from the future remnant, due to the anatomical location of the lesion(s), (3) an impaired general health status and/or serious cardiopulmonary comorbidities, and (4) an inaccessible abdominal cavity due to extensive previous abdominal surgery.

In the last two decades several radical intent thermal and non-thermal ablative therapies to treat unresectable CRLM emerged. The most well-known are radiofrequency ablation (RFA), microwave ablation (MWA), irreversible electroporation (IRE), and stereotactic ablative body radiotherapy (SABR) [17–24].

There is an ample amount of studies that have shown needle-guided thermal ablation to be effective and safe in the treatment of CRLM ≤ 3 cm [17]. After a median follow-up of 9.7 years, the EORTC-CLOCC trial reported a superior OS of RFA plus chemotherapy over chemotherapy alone (HR = 0.58; 95% CI 0.38–0.88) with an 8-year OS of 35.9% vs. 8.9% [25]. The efficacy of thermal ablation is even being compared to resection in CRLM < 3 cm to prove non-inferiority in the ongoing RCT COLLISION [26]. Conversely, for larger (> 3 cm) CRLM, the primary technique efficacy decreases exponentially, manifesting in higher rates of local tumour progression for all techniques [27–33].

The radiation oncology community has suggested SABR to represent a feasible alternative as local treatment option for a limited number of unresectable CRLM. Although SABR can be effective to establish local control, a trade-off exists between tumour control and collateral damage to surrounding tissue and structures [34–36]. As the efficacy is unaffected by the proximity of large blood vessels and less affected by lesion size and a difficult-to-reach anatomical location, authors have suggested SABR as an alternative to thermal ablation for perivascular, sub-diaphragmatic, and larger CRLM [37, 38].

IRE is a relatively new non-thermal ablative method, where cell death is caused by high-voltage electric pulses that induce permanent disruption of the membrane [39]. It is thought to be a safe ablation method for tumours adjacent to vascular and biliary structures because it spares the extracellular matrix and as a result preserves critical tubular structures [40].

Extrapolating treatment results of small-sized CRLM, local ablative therapies are also often presumed to prolong survival for unresectable intermediate-size CRLM (3–5 cm). However, given the exponential decrease in local efficacy with increasing lesion size, this presumption requires validation. To ensure patients receive the optimal treatment method, knowledge about the preferred local ablative technique is indispensable. This multidisciplinary systematic review and meta-analysis critically assess and compare the outcomes of local treatment in patients with unresectable intermediate-size CRLM treated with the most widely used thermal and non-thermal ablation techniques.

**Methods**

This systematic review and meta-analysis was written according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and PICO (patients, interventions, comparisons, outcomes) protocol [41].

**Search**

A literature search was performed in the databases PubMed and Embase from January 1st 2008 till November 11th 2020. Keywords used in the search were as follows: colorectal liver metastases, microwave ablation, radiofrequency ablation, stereotactic body radiotherapy, and irreversible electroporation. The full search strategy is presented in appendix 1. The subsequent PICO question was used for the search strategy: P(population): patients with intermediate-size CRLM; intervention: RFA, MWA, IRE, and SABR with or without systemic therapy; comparison: systemic therapy alone; outcome: critical endpoints were local-tumour-progression-free survival/local control (LTPFS/LC), complications/toxicity, overall survival (OS), and important endpoints were disease-free survival (DFS) and quality of life. The interventional oncology society prefers the use of the term LTPFS (to describe the time from the initial treatment to the first recurrence, regardless of whether the recurrence was reablated), where the radiation oncology society prefers the use of the term local control [42]. Conference abstracts, reviews, meta-analyses, and studies not concerning humans were excluded.

**Study Selection**

The abstracts retrieved by this literature search were independently screened by two authors (SN and RP). If the abstracts appeared to adhere to the in- and exclusion criteria, a full-text evaluation was performed. The references of relevant publications were reviewed. References appearing eligible were also submitted to a full-text evaluation. Manuscripts also
containing information on efficacy and safety of primary liver carcinoma and non-colorectal liver metastases were allowed if they reported their data on CRLM separately. Studies were excluded if they did not report on at least one of the above-mentioned outcome measures distinctly for intermediate size CRLM and if the sample size was less than five. Discrepancies between authors were resolved by consensus.

Data Extraction

Two authors (SN and MD) extracted the data from the included studies. This concerned the following variables: name author, publication year, years of inclusion, total number of patients, and number of patients with CRLM 3–5 cm, whether patients received prior local treatment of the liver, presence of extrahepatic disease, size of CRLM, amount of CRLM 3–5 cm and/or ≥3 cm, treatment modality, and concomitant resections with thermal ablation. The collected data pertaining to study outcomes were for example median follow up, dose and fractions in SABR and biologically equivalent dose (BED10), local control, LTPFS, complications/toxicity, DFS, OS, and quality of life. This data was checked by a third author (RP). In case of discrepancies, these were discussed and resolved by consensus. Additional data of subgroups with intermediate size CRLM was requested and collected from authors that reported results of the comparison of SABR to thermal ablation.

Data Analysis

Quality assessment criteria per study were based on clinical criteria, such as the included number and specific reporting of intermediate-size CRLM, the population, and the outcome measures used. Pooled analyses were allowed if results from studies were sufficiently similar with regards to these criteria. Studies potentially sufficient to perform meta-analysis were assessed and a random effects model was used to account for statistical heterogeneity. Analysis with the Mantel–Haenszel method was performed to calculate risk ratios (RR) of local tumour progression. Review Manager 5.3 was used to perform the meta-analysis.

Guidelines

CRLM guidelines were searched using Guideline Central and Guidelines International Network databases.

Results

The search strategy yielded 1685 abstracts after removal of duplicates. After screening the abstracts for eligibility, 151 articles remained for full-text analysis, of which 124 were excluded. This left 27 articles that met our inclusion criteria for qualitative synthesis and 2 articles for quantitative synthesis with meta-analysis (see flowchart in Figs. 1 and 2). Very few publications reported on the outcomes of intermediate-size CRLM (3–5 cm) specifically. Therefore, we allowed publications reporting on the outcomes of CRLM ≥3 cm. Series that discontinued including patients before 2008 were excluded, due to the likelihood of outdated results.

Study Characteristics

There were no randomized controlled trials on ablative treatment methods for intermediate-size CRLM. Of 27 included articles, 20 retrospective series [27, 43–61], and 1 prospective cohort [62] reported on thermal ablation for CRLM >3 cm: 14 on RFA [27, 43, 45–49, 51, 53, 56–59, 62], 5 on MWA [44, 52, 54, 60, 61], and 2 on both RFA and MWA [50, 55]. One phase II trial [35] and two retrospective series [63, 64] report the outcome of SABR for CRLM >3 cm. One study reported outcomes for intermediate-size CRLM treated with IRE [65]. Two retrospective series compared SABR to thermal ablation and were included in the meta-analysis [66, 67]. All publications were issued between 2011 and 2020. In the absence of comparative studies, a formal meta-analysis could not be performed. The study population (patient, disease, and lesion characteristics), the use of periprocedural systemic therapy, and oncological outcome measures were highly variable and heterogeneously reported.

Thermal Ablation

Patient and Lesion Characteristics

At per patient level, eleven studies reported on 323 patients with at least one ablated CRLM >3 cm [45–49, 51, 53, 54, 58, 59, 62] (see Table 1). Although simultaneous resections of concomitant resectable CRLM were allowed in 6 studies, none reported outcomes specifically for ablated intermediate-size CRLM with versus without concomitant partial hepatectomy [27, 44, 45, 48, 55, 57]. Half of the studies stated whether patients had received prior focal liver treatment(s) (range 9.1–100%) [27, 43, 46, 50, 51, 53, 56–59]. Extrahepatic disease was allowed in 11 studies [27, 45–47, 51–53, 55–59, 62], disallowed in 5 [43, 48, 49, 54, 60], and not reported in 3 [44, 50, 61]. On a per-lesion basis, 18 studies reported on 760 ablated CRLM >3 cm: 544 with RFA; 160 with MWA; 56 RFA or MWA [27, 43–50, 52–61].
Overall Survival

Colorectal Liver Metastases 3–5 cm

Seven studies reported on OS in patients with at least one intermediate-size CRLM [43, 45, 51, 54, 58, 60, 62]. Median survival ranged 24–39 months [43, 45, 51, 54, 58, 60, 62]. Fan et al. reported the lowest median OS of 24 months [62]. However, in this study patients received cytoreductive RFA with palliative intent in salvage setting. Excluding the outlying results from Fan et al., OS ranged 26–39 months. The 1-, 2-, 3-, and 5-year OS ranged 73–92% [43, 54, 58, 62], 41–72% [43, 54, 58, 62], 20–40% [43, 45, 54, 58, 62], and 10–36% [43, 45, 54, 62], respectively.

Colorectal Liver Metastases > 3 cm

Median OS ranged 21.7–37 months in seven retrospective series [27, 43, 46, 48, 53, 57, 59]. The lowest median OS was reported by Veltri et al. [57], a relatively old study that included patients over a longer period of time from 1996 to 2009. More than 40% of their study population had received prior local hepatic treatment and almost 20% of patients presented with extrahepatic disease. The 1-, 2-, 3-, and 5-year OS

Fig. 1 Flowchart of systematic search and selection according to PRISMA

Fig. 2 Risk ratio of local tumour progression comparing SABR to thermal ablation (TA)
| Author/year         | Type of study | Yrs of inclusion | MWA/ RFA | No pts in tot | No pts CRLM > 3 cm | Age* yrs | Lap/open/perc * | EHD* | Prior local treatment of liver * | Concurrent surgery* | Median FU in months * |
|---------------------|---------------|------------------|----------|---------------|---------------------|----------|-----------------|------|-----------------------|---------------------|----------------------|
| Bale/2011 [43]     | Retro         | 2005–2011        | RFA      | 63            | -                   | Med 66   | Perc            | No   | 38% of pt             | No                  | 25                   |
| Eng/2015 [44]      | Retro         | 2009–2013        | MWA      | 33            | -                   | Med 61   | Open            | -    | -                      | 28 pt (85%)         | 17                   |
| Erten/2020 [61]    | Retro         | 2014–2019        | MWA      | 94            | -                   | Mean 61.6| Lap/open        | -    | -                      | -                   | 18                   |
| Fan/2016 [62]      | Prosp         | 2003–2010        | RFA      | 49            | 18                  | -        | -               | Yes  | -                      | -                   | -                    |
| Gwak/2011 [45]     | Retro         | 2004–2008        | RFA      | 35            | 10                  | Med 62   | Perc 26pt/open 9 pt | 7 pt 20% | No | 9 pt (26%)             | 31                   |
| Bale/2011 [43]     | Retro         | 2002–2010        | RFA      | 84            | 31                  | Med 64.6 | Perc            | 23 pt 27% | 21 pt (25%) | No                  | 26                   |
| Jiang/2019 [47]    | Retro         | 2012–2016        | RFA      | 76            | 22                  | -        | Perc            | 40 pt 53% | -    | No                  | 32                   |
| Kennedy / 2012 [48]| Retro         | 2000–2010        | RFA      | 130           | 46                  | Med 65   | Lap             | No    | -                      | 42 pt (32%)         | 42                   |
| Kim / 2011 [49]    | Retro         | 1996–2008        | RFA      | 177           | 14                  | Mean 60.4| Perc/open       | No    | -                      | -                   | 41                   |
| Liu/2017 [50]      | Retro         | 2004–2013        | RFA/MWA  | 101           | -                   | Mean 58.2| Perc            | -    | 25 pt, (25%)          | No                  | -                    |
| Mao/2019 [51]      | Retro         | 2006–2016        | RFA      | 61            | 25                  | Med 59   | Perc            | 8 pt 13.1% | 61 pt (100%) | No                  | 29                   |
| Nielsen/2013 [27]  | Retro         | 2000–2010        | RFA      | 128           | -                   | Mean 62.6| Perc/open       | Yes   | 12 pt (9%)            | 64                   | 36                   |
| Qin/2018 [52]      | Retro         | 2013–2017        | MWA      | 137           | -                   | Mean 54.9| Perc            | 34 pt 25% | -    | No                  | 18                   |
| Shady/2015 [53]    | Retro         | 2002–2012        | RFA      | 162           | 26                  | -        | Perc            | 51 pt 31% | 116 pt (72%) | No                  | 55                   |
| Shi/2020 [54]      | Retro         | 2010–2017        | MWA      | 210           | 68                  | Mean 59  | Perc            | No    | -                      | No                  | 48                   |
| Takahashi/2018 [55]| Retro         | 2011–2014        | RFA/ MWA | 105           | -                   | -        | Lap             | Yes   | 24 pt (23%)           | MWA 17 RFA 18       | -                    |
| Valls/2015 [56]    | Retro         | 2005–2012        | RFA      | 59            | -                   | Mean 64.1| Perc            | Yes   | 59 pt (100%)          | -                   | 25                   |
| Veltri/2012 [57]   | Retro         | 1996–2009        | RFA      | 248           | -                   | Med 67   | Perc 243 pt/ open 19 pt | 51 pt (20%) | 102 pt (41%) | 19 pt (8%)            | 19                   |
| Wang/2020 [58]     | Retro         | 2013–2018        | RFA      | 85            | 37                  | Mean 59  | Perc            | 22 pt (26%) | 20 pt (24%) | No                  | 30                   |
| Wang/2020 [59]     | Retro         | 2012–2016        | RFA      | 80            | 26                  | Mean 59  | Perc            | 28 pt (35%) | 12 pt (15%) | No                  | 51                   |
| Zhang/2016 [60]    | Retro         | 2009–2014        | MWA      | 199           | -                   | Med 60   | Perc            | No    | -                      | No                  | 30                   |

*Of total amount of patients
ranged 74–93%, 30–70%, 20–34%, and 8–31% [48, 49, 53, 57, 59]. See Table 2 for an overview of the survival outcomes.

**Complications and Quality of Life**

None of the studies reported the complication rate or the effect of thermal ablation on quality of life specifically for patients with CRLM > 3 cm. Irrespective of lesion size studies reported a major complication rate of 2–17% for percutaneous ablation [43, 46, 47, 50, 52, 53, 56]. Most reported major complications were: pleural effusion, pneumothorax, hepatic abscess, hepatic hematoma, perihepatic bleeding, or ileal perforation. Both Qin et al. and Veltri et al. did not find a correlation between the development of complications and lesion size [52, 57]. Qin et al. found a mean lesion size of 1.8 cm vs 1.5 cm for patients with versus without complications (p = 0.101) [52]. Similarly, Veltri et al. found a mean size of 2.7 cm in both groups [57].

**Disease-Free Survival, Local-Tumour-Progression-Free Survival, and Local Control**

**Colorectal Liver Metastases 3–5 cm**

Two retrospective series reported DFS [45, 60]. Gwak et al. reported a median DFS of 19 months [45] and Zhang et al. reported a median DFS of 12 months for patients with CRLM of 4–5 cm [60]. One prospective cohort found a median DFS of 15 months [62]. In four retrospective series, LTP rate varied between 25 and 62% with a median follow up time of 25–36 months [27, 43, 51, 58]. Eventual local control following repeat-ablations was not reported specifically for intermediate-size CRLM. See Table 3 for an overview of the efficacy of thermal ablation.

**Colorectal Liver Metastases > 3 cm**

Bale et al. [43] reported a median DFS of 12.4 months from stereotactic RFA. Shady et al. found a median LTPFS of 6 months [53] and Wang of 9 months [59]. Kim et al. found a 5-year DFS rate of 23% [49]. LTP was reported by nine retrospective series and ranged 14–78% with a median follow up time of 17–55 months [44, 46, 48, 50, 52, 53, 55, 56, 61]. The 1- and 2-year LTPFS varied between 34.8–69% and 17.4–62%, respectively [46, 47, 53, 55, 59].

**Stereotactic Ablative Body Radiotherapy**

**Patient and Lesion Characteristics**

Strict adherence to the inclusion criteria resulted in two retrospective series, as most SABR series do not report separate results based on tumour type and tumour diameter > 3 cm [63, 64]. Doi et al. compared SABR with a conventional fractionated schedule and included 24 patients in total, 15 patients with 21 CRLM > 3 cm and 16 patients (66.7%) with a history of focal hepatic resection(s) and/or thermal ablation(s) [63] (see Table 4). Joo et al. included 70 patients in total, half of the study population had received prior local hepatic treatment, and 19 patients (27%) presented with extrahepatic disease [64]. It was not stated how many patients had intermediate size CRLM.

To collect more data, one prospective phase II trial that studied the efficacy of SABR for 27 CRLM patients with a cumulative gross tumour volume (GTV) diameter > 3 cm unsuitable for surgery and thermal ablation was eventually added [35]. Cumulative GTV diameter here means either at least 1 CRLM > 3 cm or multiple smaller CRLM with a cumulative size > 3 cm. Twenty-four CRLM > 3 cm were included. In this study, 11 patients (26%) had extrahepatic disease (EHD) and half of the patients had undergone prior focal liver treatment(s).

**Overall Survival**

No study reported OS specifically for CRLM 3–5 cm. Doi et al. reported results both for SABR as for non-ablative radiotherapy and found a median OS of 45 months for patients with at least one CRLM > 3 cm [63]. Conversely, for patients with small-size CRLM ≤ 3 cm, they found a median OS of 27 months [63]. Scorsetti et al. reported a 1-, 2-, and 3-year OS from SABR of 68, 40, and 17%, respectively, for patients with CRLM > 3 cm [35] (Tables 5 and 6).

**Toxicity and Quality of Life**

No studies reported the complication rate or the effect of SABR on quality of life for patients with CRLM > 3 cm. Two studies reported no grade ≥ 3 toxicity [35, 64]. Scorsetti et al. found grade 2 acute toxicity in 78% of the study population (55% fatigue, 25% transient hepatic transaminase increase, 12% nausea) [35]. One series reported 2/24 patients with grade 3 toxicity, 1 patient with grade 3 γ-glutamyl transpeptidase (GGT) elevation, and 1 patient with grade 3 GGT and blood bilirubin elevation presumably caused by cholangitis due to a recurrent tumour [63].

**Disease-Free Survival and Local Control**

Doi et al. found a 1- and 2-year local control of 50.4% and 10.5% for intermediate-size CRLM and 71.4% and 26.8% for large-size CRLM > 5 cm, respectively [63]. Joo et al. reported a local control for CRLM > 3 cm that correlated with the delivered radiation dose (BED < 132 Gy vs. ≥ 132 Gy): 67% vs 90% (p = 0.06).
Table 2 Overview of OS outcomes in thermal ablation

| Author | Lesion size (range) cm * | No. CRLM 3–5 cm | No. CRLM > 5 cm | No. CRLM > 3 cm | Median OS in months | 1 yr OS 3–5 cm | 2 yr OS 3–5 cm | 3 yr OS | 5 yr OS |
|--------|--------------------------|------------------|----------------|----------------|--------------------|----------------|----------------|--------|--------|
| Bale [43] | 2 (0.5–13) | 36 | 23 | 59 | 32 | > 3 cm: 31 > 5 cm 29 | 86%^ | 72%^ | 36%^ | 36%^ |
| Fan [62] | NS (till 5 cm) | - | - | - | 24 | - | 73%^ | 41%^ | 20%^ | 10%^ |
| Gwak [45] | 2.4 (1–5) | - | - | - | Mean 39 | - | - | 40% | 27% |
| Hamada [46] | 2.3 (0.5–9.0) | - | - | 35 | 31 | - | - | - | - |
| Kennedy [48] | 2.9 (1–8) | - | - | 46 | 29 | > 3 cm 93% | > 3 cm 70%^ | > 3 cm 34% | > 3 cm 8% |
| Kim [49] | 2.1 (0.5–6.2) | - | - | 14 | - | > 3 cm 84%^ | > 3 cm 53%^ | > 3 cm 31%^ | > 3 cm 31%^ |
| Mao [51] | 2.7 (0.9–4) | - | - | - | 32 | - | - | - | - |
| Nielsen [27] | 2.2 (0.2–8.0) | 49 | 20 | 69 | 37 | - | - | - | - |
| Shady [53] | 1.8 (0.5–5.7) | - | - | 32 | 25 | > 3 cm 88%^ | > 3 cm 50%^ | > 3 cm 26%^ | > 3 cm 18%^ |
| Shi [54] | 2.7 (till 5 cm) | 68 | - | - | 26 | - | 92%^ | 55%^ | 32%^ | 20%^ |
| Veltri [57] | 2.5 (NS) | - | - | 137 | 21.7 | > 3 cm 74%^ | > 3 cm 39%^ | > 3 cm 30%^ | > 3 cm 14%^ |
| Wang [58] | 2.8 (0.8–5) | 52 | - | - | 26 | - | 90%^ | 42%^ | 33%^ | - |
| Wang [59] | 2.5 (1–6.4) | - | - | 32 | 22 | > 3 cm 80%^ | > 3 cm 30%^ | > 3 cm 20%^ | > 3 cm 10%^ |
| Zhang [60] | 3 (1–5) | 51 (4–5 cm) | - | - | 36 | - | - | - | - |

NS, not stated
*All-size CRLM included in study
^Percentages retrieved and estimated from OS curves
Irreversible Electroporation

Patient and Lesion Characteristics

The search resulted in one retrospective series specifically reporting on treatment of intermediate-size CRLM [65]. Fruhling et al. reported on 30 patients in total, of which nine patients had 9 CRLM of 3–4 cm in size. More than half of the patients had received previous local treatment(s) of the liver and all patients were treated by percutaneous IRE. Median follow-up was 22.3 months.

To extend data on IRE for CRLM > 3 cm we included the final results of an as of yet unpublished prospective multicentre phase IIb single-arm study (COLDFIRE-2 trial) where 51 patients were treated with IRE in 62 procedures. Although currently under review, the trial protocol was previously published [68], the results have been presented at ECI0 2019 in Amsterdam, and the outcomes are available as online abstract [69]. Twenty-one (27.6%) out of the 76 IRE-treated CRLM were 3–5 cm in size.

Overall Survival

Fruhling et al. reported a median OS from IRE for intermediate-size CRLM of 19.7 months [65]. Meijerink et al. reported a median OS from IRE of 32.4 months (95% CI 19.2–45.6 months), although they did not report median OS specifically for the subgroup of patients with intermediate-size CRLM.

Complications and Quality of Life

Fruhling et al. reported four complications in nine patients after IRE of intermediate-size CRLM. Three patients with CTCAE grade II/II complications (episode of shortness of breath, of increased blood pressure and ECG changes during IRE and chest pain requiring morphine) and one patient with a CTCAE grade III complication, namely, a portal vein and biliary duct stricture in the IRE ablated zone. A stent was placed for the portal vein stricture and a percutaneous trans-hepatic cholangiography (PTC) drainage catheter was

Table 3  Overview of efficacy outcomes of thermal ablation

| Author   | Lesion size (range) cm * | No. CRLM 3–5 cm | No. CRLM > 3 cm | LTP 3–5 cm 11% | LTP > 3 cm | 1 yr LTPFS | 2 yr LTPFS | DFS/LTPFS (in months) |
|----------|--------------------------|-----------------|----------------|---------------|-----------|------------|------------|-----------------------|
| Bale     | 2 (0.5–13)               | 36              | 59             | -             | -         | -          | -          | DFS > 3 cm 12         |
| Eng      | NS (till 5.5)            | 7               | -              | 14%           | -         | -          | -          | DFS > 5 cm 11         |
| Erten    | NS (0.2–6.6)             | -               | 21             | 19%           | -         | -          | -          |                      |
| Fan      | NS (till 5 cm)           | -               | -              | -             | -         | -          | -          | Med DFS 3–5 cm: 15    |
| Gwak     | 2.4 (1–5)                | 27              | -              | -             | -         | -          | -          | Mean DFS 3–5 cm, 3-yr 20% 5-yr 10% |
| Hamada   | 2.3 (0.5–9.0)            | -               | 35             | 69%           | 35%       | 17%        | -          |                      |
| Jiang    | 2.3 (0.9–5.7)            | -               | 33             | -             | 67%       | 62%        | -          |                      |
| Kennedy  | 2.9 (1–8)                | -               | 46             | -             | 20%       | -          | -          |                      |
| Kim      | 2.1 (0.5–6.2)            | -               | 14             | -             | -         | -          | -          | DFS rate 23%          |
| Liu      | 2.1 (0.7–6.0)            | -               | 23             | -             | 65%       | -          | -          |                      |
| Mao      | 2.7 (0.9–4)              | -               | -              | 25% per tumour, 28% per pt | -   | -          | -          |                      |
| Nielsen  | 2.2 (0.2–8.0)            | 49              | 69             | 27%           | -         | -          | -          |                      |
| Qin      | 1.5 (0.5–6.7)            | 12              | 13             | -             | 38%       | -          | -          |                      |
| Shady    | 1.8 (0.5–5.7)            | -               | 32             | -             | 78%       | 36%^       | 25%^      | Med LTPFS 6           |
| Takahashi| ≥3–NS                    | -               | 33             | -             | 45%       | 69%^       | 40%^      |                      |
| Vallis   | 3–5.8                    | -               | 25             | -             | 52%       | -          | -          |                      |
| Wang     | 2.8 (0.8–5)              | 52              | -              | 62%           | -         | 60%^       | 39%^      |                      |
| Wang     | 2.5 (1–6.4)              | -               | 32             | -             | -         | -          | -          | Med LTPFS 9           |
| Zhang    | 3 (1–5)                  | 51 (4–5 cm)     | -              | -             | -         | -          | -          | Med DFS 4–5 cm 12     |

NS, not stated
*Of total amount of patients
^Percentages retrieved from graphs

Irreversible Electroporation

Patient and Lesion Characteristics

The search resulted in one retrospective series specifically reporting on treatment of intermediate-size CRLM [65]. Fruhling et al. reported on 30 patients in total, of which nine patients had 9 CRLM of 3–4 cm in size. More than half of the patients had received previous local treatment(s) of the liver and all patients were treated by percutaneous IRE. Median follow-up was 22.3 months.

To extend data on IRE for CRLM > 3 cm we included the final results of an as of yet unpublished prospective multicentre phase IIb single-arm study (COLDFIRE-2 trial) where 51 patients were treated with IRE in 62 procedures. Although currently under review, the trial protocol was previously published [68], the results have been presented at ECI0 2019 in Amsterdam, and the outcomes are available as online abstract [69]. Twenty-one (27.6%) out of the 76 IRE-treated CRLM were 3–5 cm in size.

Overall Survival

Fruhling et al. reported a median OS from IRE for intermediate-size CRLM of 19.7 months [65]. Meijerink et al. reported a median OS from IRE of 32.4 months (95% CI 19.2–45.6 months), although they did not report median OS specifically for the subgroup of patients with intermediate-size CRLM.

Complications and Quality of Life

Fruhling et al. reported four complications in nine patients after IRE of intermediate-size CRLM. Three patients with CTCAE grade II/II complications (episode of shortness of breath, of increased blood pressure and ECG changes during IRE and chest pain requiring morphine) and one patient with a CTCAE grade III complication, namely, a portal vein and biliary duct stricture in the IRE ablated zone. A stent was placed for the portal vein stricture and a percutaneous trans-hepatic cholangiography (PTC) drainage catheter was
### Table 4  Overview of included studies reporting on SABR

| Author/ year | Type of study | Yrs of inclusion | Treatment modality | No pts in tot | No pts CRLM > 3 cm | Age* yrs | Dose, fractions, (BED10) | EHD* | Prior local treatment of liver * | Lesion size (range) cm | Median FU in months * |
|--------------|---------------|------------------|--------------------|---------------|---------------------|----------|--------------------------|------|-------------------------------|----------------------|---------------------|
| Doi/2017 [63] | Retro         | 2007–2014        | LINAC              | 24            | 15                  | 64 med   | 45.0–72.0 Gy, 4–33 fr (71.7–115.5 Gy) | -    | 16 pt (66.7%)                | 3.5 (0.7–11.69)       | 16.5                |
| Joo/2017 [64] | Retro         | 2007–2014        | LINAC              | 70            | -                   | 65 med   | 30–60 Gy, 3–5 fr (58.4–180 Gy)       | 19 pt (27%) | 35 pt (50%)                  | 2.9                  | 34.2                |
| Scorsetti/ 2015 [35] | Phase II | 2010–2012        | LINAC              | 42            | 27pt^             | 67 mean  | 45.6–85.7 Gy/3fr (262.5 Gy)         | 21 pt (50%) | 3.5 (1.1–5.4)               | 24                  |                     |

*Percentages retrieved from graphs

### Table 5  Overview of OS and Local Control for SABR

| Author | No. CRLM 3–5 cm | No. CRLM > 5 cm | No. CRLM > 3 cm | Median OS > 3 cm | 1 yr OS | 2 yr OS | 3 yr OS | LC > 3 cm | 1 yr LC | 2 yr LC | LTPFS |
|--------|-----------------|-----------------|-----------------|------------------|---------|---------|---------|-----------|---------|---------|-------|
| Doi    | 13              | 8               | 21              | 45 mo            | -       | -       | -       | -         | -       | -       | 3–5 cm | 15 mo |
| Joo    | -               | -               | 42              | -                | -       | -       | -       | -         | BED > 132 Gy 67%, BED > 132 Gy 90% | -       | -       |       |
| Scorsetti [35] | -     | -               | 24              | > 3 cm 68%      | > 3 cm 40% | 17%^    |       | -         | -       | -       |       |

*Percentages retrieved from graphs

*Of total amount of patients

^27 patients with cumulative GTV ≥ 3 cm, not actual lesion size > 3 cm
placed for the biliary duct stricture. Meijerink et al. did not report complications for CRLM 3–5 cm and both series did not report the effect of IRE on quality of life [65].

### Disease-Free Survival, Local-Tumour-Progression-Free Survival, and Local Control

DFS was not reported specifically for CRLM > 3 cm. After a median follow up of 22.3 months, in five out of nine patients (55.6%), local-tumour-progression was detected [65]. Meijerink et al. did not find a significant difference in LTPFS between small- and intermediate-size CRLM (HR 1.72; CI 0.73–4.06; p = 0.22) [69]. With a minimum follow-up of 1 year, median per-patient and per-tumour LTPFS was not reached. Including repeat procedures, local control was eventually realized in 74% (37/50) of patients.

### Comparison of SBAR to Thermal Ablation

#### Local Tumour Progression

Franzese et al. performed a propensity score–based comparison of SABR to MWA in 135 patients with CRLM with freedom from local progression (FFLP) as primary endpoint [66]. Stratified analysis by lesion size showed that SABR improved FFLP in patients with lesions > 3 cm and FFLP was similar for both treatment techniques in patients with lesions ≤ 3 cm. Additional data collection showed FFLP specifically for intermediate-size CRLM, suggesting a benefit in local control of SABR compared to MWA in the treatment of larger lesions. After at least 1 year of follow-up, local tumour progression was reported in 8 of 39 CRLM for SABR and 11 of 30 CRLM for MWA of intermediate-size lesions.

Nieuwenhuizen et al. performed a multivariate analysis of thermal ablation compared to SABR for unresectable CRLM to evaluate local tumour progression in the prospective AmCORE registry [67]. Subgroup analyses were performed for larger size lesions (> 3 cm) and additional data collection showed local tumour progression in 11/20 tumours following SABR and 22/41 tumours following thermal ablation with at least 1 year of follow-up.

Overall comparison of local tumour progression following SABR and thermal ablation showed no significant difference (p = 0.50).

### Guidelines

Full-text analysis was performed for 12 guidelines [70–81]. One guideline included recommendations for CRLM > 3 cm: the UK National Institute for Health and Care Excellence (NICE) guideline stated that “there is controversy over the indication for RFA, most operators will no longer consider lesions > 4 cm in diameter for treatment” [71]. All other guidelines either did not report on RFA, MWA, SABR, or IRE at all, or they did not state recommendations for CRLM > 3 cm, or they did not state size limitations.

### Discussion

Currently, the preferred treatment method for unresectable intermediate-size CLRM for patients, in whom downstaging or (further) downsizing systemic therapy failed, remains unknown. This systematic review and meta-analysis aimed to collect evidence regarding local ablative therapies to treat unresectable intermediate-size CRLM and to provide a comparison of the most well-known ablative techniques. Literature to reliably assess the oncological outcome was scarce for all treatment options. A substantial shortcoming was the

| Author/ year Type of study | Yrs of inclusion | No pts SABR/TA | Age * yrs | Median size SABR/TA | Local tumour progression SABR/TA | Median time to local tumour progression SABR/TA | Dose range SBAR | Median FU in months * |
|---------------------------|-----------------|---------------|-----------|---------------------|--------------------------------|-----------------------------------------------|---------------|----------------------|
| Franzese/2018 Retro 2009–2016 39/30 73 36.5/34.0 cm 20.5%/36.7% 20.0/13.9 months 50.25–75 Gy 24.5 | | | | | | | | |
| Nieuwenhuizen/2021 Retro 2005–2011 20/41 63 38.0/44.0 cm 55.0%/53.7% 9.0/6.0 months 40–60 Gy 29.3 | | | | | | | | |

**TA**, thermal ablation

**LTPFS**, local tumour progression free survival

*Of total cohort of the study

Table 6 Overview of studies comparing SABR to thermal ablation for intermediate size CRLM

* Springer
lack of randomized controlled trials comparing treatment methods. In addition, apart from one prospective cohort [62] and one phase II trial [35], virtually, all included studies were retrospective series, with only two of the studies making a comparison between treatment options for intermediate-size CRLM. Furthermore, the reported oncological outcomes, the study population, and the timing of interventions with regard to periprocedural systemic chemotherapy were highly heterogeneous, making it impossible to draw any conclusion.

The majority of publications on thermal ablation concerned RFA. However, for larger-size tumours, recently, preference has started to shift towards newer generation MWA systems or tumour-bracketing multiprobe ablation techniques as potentially superior alternatives to conventional RFA [82, 83]. Presumed benefits of MWA over RFA are consistently higher intratumoural temperatures, faster heating, shorter procedure time, larger ablation volumes, and less susceptibility to the “heat-sink” effect at the cost of a somewhat higher biliary tract complication rate [84–86]. Although few studies compared RFA to MWA for patients with CRLM, several retrospective cohorts reported lower local recurrence rates following MWA compared to RFA, 6% vs. 20% (p < 0.01) [19], 10% vs. 20% (p = 0.02) [55], 8.6% vs. 20.3% (p = 0.07) [87], respectively. In this review, LTP rate at median follow-up after the first ablation ranged 11–78% for RFA [27, 43, 46, 48, 51, 53, 56, 58] and 14–38% for MWA [44, 52, 61]. Although this seems to suggest a preference of MWA for CRLM > 3 cm, the number of MWA treated tumours was low (n = 41). A substantial part of the included publications on thermal ablation was relatively old. Consequently, recent advances in technique and improved awareness of the necessity to expand and confirm tumour-free margins following thermal ablation are inadequately represented [53].

For SABR, merely three articles met the inclusion criteria, and all reported different oncological outcome measures. Hence, no conclusions could be drawn regarding efficacy of SABR for intermediate-size CRLM. Many articles describing results for mixed disease and not for CRLM separately could not be included, because metastases deriving from different primary cancers or different organs containing colorectal metastases can have variable responses [88–96]. Several articles were excluded because they presented hazard ratios regarding small versus intermediate-size CRLM but did not report the actual outcomes per size-subgroup, or they reported on the size of CRLM in volumes and not diameter [34, 90, 97].

Two articles met the inclusion criteria for meta-analysis after additional data collection [66, 67]. No difference in local tumour progression was found between SABR and thermal ablation. Two excluded publications compared SABR to thermal ablation for hepatic metastases [98, 99], without specifying outcomes for intermediate-size CRLM. Stintzing et al. compared single session robotic radiosurgery (RRS) to percutaneous RFA in 2 × 30 patients and matched them for size (mean 33–34 mm) and number of lesions [98]. They found that patients treated with RRS had a longer LTPFS compared to patients treated with RFA (34.4 vs. 6.0 months; p < 0.001), recurrence rates were similar (67 vs. 63%), and there was a trend towards prolonged median OS for RFA treated patients (34.4 vs 52.3 months; p = 0.06).

A retrospective cohort by Jackson et al. compared SABR to RFA in 161 patients with liver metastases [99]. SABR demonstrated a superior FFLP compared to RFA, especially for hepatic metastases ≥ 2 cm. There was no difference in median OS (25.9 months for RFA vs. 24.5 months for SABR). These studies, compared to the included studies in meta-analysis, imply a superior local control of SABR compared to thermal ablation for larger-size lesions. However, only comparing local control rates following one ablative procedure seems unjust when comparing a repeatable technique (RFA, MWA) with a technique that usually does not allow for retreatment (SABR). No studies reported a direct comparison of thermal ablation to SABR with regard to periprocedural complications and toxicity for intermediate-size CRLM, though both techniques are associated with an exceptionally low mortality and morbidity rate. Given the comparable overall reported mortality of 0.16% for thermal ablation [100] and 0.5% for SABR [101] (with 3/656 patients mistakenly published as 0.004%) and given the comparable serious adverse event rate of 4–5% for thermal ablation and 9% for SABR [100, 101]. Because both ablative probes and ionizing radiation will potentially result in collateral morbidity by invading surrounding healthy tissue, we prefer to refrain from using the term non-invasive for SABR.

Only two studies concerning IRE were included in this review. This low number can be explained by the relative novelty of this technique and because it is generally a niche indication for CRLM unsuitable for resection and thermal ablation due to close proximity to biliary or vascular structures [40]. Interestingly, the results of the prospective phase II trial (COLDFIRE-2) did not reveal a difference in 1-year LTPFS for small-size versus intermediate-size CRLM, which may indicate that IRE, where electrodes bracket tumours, is less susceptible to differences in size [102].

A recent multidisciplinary consensus document concerning resectability and ablatability criteria for liver only colorectal metastases did not provide strict recommendations for unresectable intermediate-size CRLM due to a lack of evidence and also stated that the exact roles of SBRT and IRE in the treatment of unresectable CRLM need to be further investigated [103].

Although systematically acquired, the results of this systematic review and meta-analysis should be judged with restraint, as only a limited amount of studies could be
included, with poor quality and heterogeneous study populations. There is a high risk of publication bias due to the inclusion of mainly retrospective observational studies.

**Conclusion**

There are no randomized controlled trials or comparative studies on local treatment for patients with intermediate-size unresectable CRLM. Heterogeneity of the reported oncological outcomes and study populations reduced the amount of obtained data suitable for pooled assessment. Although long-term disease control was described in subsets of patients in all series, there is a lack of studies directly comparing RFA to MWA or to SABR or IRE. No hard conclusions or recommendations can be drawn and further prospective research is necessary to determine what local treatment option, if any, is preferable for intermediate-size unresectable CRLM, preferably in the setting of randomized controlled trials. Therefore, we strongly support the ongoing trials, the COLLISION-XL trial NCT04081168 (unresectable colorectal liver metastases: stereotactic body radiotherapy versus microwave ablation — a phase II randomized controlled trial for CRLM 3–5 cm), an RCT in Denmark for CRLM < 4 cm NCT03654131 (stereotactic body radiation therapy vs microwave ablation for colorectal cancer patients with metastatic disease in the liver), and an RCT in Italy for CRLM < 4 cm NCT02820194 (a trial on SABR versus MWA for inoperable colorectal liver metastases). Hopefully, the results of these trials will clarify and define the role of local ablative methods for the curative intent treatment of permanently unresectable intermediate-size CRLM.

**Appendix 1**

Pubmed search:

("Colorectal Neoplasms"[Mesh] OR ((colorectal*[tiab] OR colon*[tiab] OR rectal*[tiab] OR rectum*[tiab] OR sigmoid) AND (neoplas*[tiab] OR cancer*[tiab] OR carcinoma*[tiab] OR tumour*[tiab] OR tumours*[tiab] OR tumour*[tiab] OR tumors*[tiab] OR metastast*[tiab] OR malig*[tiab]))) AND ("Liver Neoplasms"[Mesh] OR ((liver*[tiab] OR hepatic*[tiab]) AND (cancer*[tiab] OR neoplas*[tiab] OR tumour*[tiab] OR tumours*[tiab] OR tumor*[tiab] OR tumors*[tiab] OR carcinoma*[tiab] OR metastast*[tiab] OR malig*[tiab]))) AND ("Radiosurgery"[Mesh] OR "Microwaves"[Mesh] OR “Electroporation”[Mesh] OR “Radiofrequency ablation”[Mesh] OR stereotactic body radiation therap*[tiab] OR stereotactic body radiotherapy*[tiab] OR electrocoagulation or microwave ablation*[tiab] OR MWA*[tiab] OR microwave thermosphere ablati*[tiab] OR RFA*[tiab] OR ((radiofreq*[tiab] OR radio-freq*[tiab] OR thermal*[tiab] AND (ablatt*[tiab]))). 

Embase search:

('colon cancer'/exp OR 'colon cancer' OR 'rectum cancer'/exp OR 'rectum cancer' OR (((colorectal OR colon* OR rect* OR sigmoid) NEAR/5 (neoplas* OR cancer* OR carcin* OR tumour* OR tumor* OR metastas*)):ab,ti,kw)) AND (liver metastasis'/exp OR (((liver OR hepatic*) NEAR/5 (cancer* OR tumour* OR tumor* OR neoplas* OR malign* OR carcinom* OR metastas*)):ab,ti,kw)) AND (radiosurgery'/exp OR 'microwave radiation'/exp OR 'irreversible electroporation'/exp OR 'stereotactic body radiation therap*':ab,ti,kw OR 'stereotactic body radiotherapy*':ab,ti,kw OR 'stereotactic ablative body radiotherapy*':ab,ti,kw OR 'stereotactic ablative body radiation therap*':ab,ti,kw OR SBRT*[tiab] OR SABR*[tiab] OR SBR*[tiab] OR irreversible electroporation OR IRE OR electrocoagulation OR electroporpermeabilization OR electrocoagulation OR microwave ablation*[tiab] OR MWA*[tiab] OR microwave thermosphere ablation*[tiab] OR RFA*[tiab] OR ((radiofreq*[tiab] OR radio-freq*[tiab] OR thermal*[tiab]) AND (ablatt*[tiab]))).

**Author Contribution** SN and MRM contributed to the study design. Data collection and analysis were performed by SN, MD, RSP, and MRM. The first draft of the manuscript was written by SN and MD, and all authors commented on previous versions of the manuscript and all authors read and approved the final manuscript.

**Data Availability** Not applicable.

**Code Availability** Not applicable.

**Declarations**

**Conflict of Interest** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. WHO. Estimated age-standardized incidence rates (World) in 2018, all cancers, both sexes, all ages 2018 [Available from: http://gco.iarc.fr/today/online-analysis-map Accessed 26–11–2018.]

2. Manfredi S, Lepage C, Hatem C, Coameur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254–9.

3. Hackl C, Neumann P, Gerken M, Loss M, Klinikhammer-Schalke M, Schlitt HJ. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014;14:810.

4. Engstrand J, Nilsson H, Stromberg C, Jonas E, Freedman J. Colorectal cancer liver metastases - a population-based study on incidence, management and survival. BMC Cancer. 2018;18(1):78.

5. Kopez S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27(22):3677–83.

6. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet. 1994;343(8910):1405–10.

7. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77(11):1241–6.

8. Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM. The natural history of hepatic metastases from colorectal cancer: a comparison with resective treatment. Ann Surg. 1984;199(5):502–8.

9. House MG, Ito H, Gonen M, Fong Y, Allen PJ, DeMatteo RP, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010; 210(5):744-52, 52-5.

10. Kanas GP, Taylor A, Primrose JN, Langeberg WL, Kelsh MA, Mowat FS, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283–301.

11. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–15.

12. Elfink AKE, Nieuwenhuizen S, van den Tol MP, Burgmans MC, Prevo T, Coolsen MME, et al. Hospital variation in combined liver resection and thermal ablation for colorectal liver metastases and impact on short-term postoperative outcomes: a nationwide population-based study. HPB (Oxford). 2021;23(6):827–39.

13. Adam R, Avisar E, Ariech A, Giachetti S, Azoulay D, Castraing D, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol. 2001;8(4):347–53.

14. Folprecht G, Gruenenberger T, Bachtold VO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(11):38–47.

15. Malik H, Khan AZ, Berry DP, Cameron IC, Pope I, Sherlock D, et al. Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study. Eur J Surg Oncol. 2015;41(4):499–505.

16. Ruers T, Punt C, Van Coevorden F, Piere JP, Borel-Rinkes I, Ledermann JA, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23(10):2619–26.

17. Meijerink MR, Puijk RS, van Tilborg A, Henningens KH, Fernandez LG, Neyt M, et al. Radiofrequency and microwave ablation compared to systemic chemotherapy and to partial hepatectomy in the treatment of colorectal liver metastases: a systematic review and meta-analysis. Cardiovasc Interv Radiol. 2018;41(8):1189–204.

18. Scheffer HJ, Melenhorst MC, Echenique AM, Nielsen K, van Tilborg AA, van den Bos W, et al. Irreversible electroporation for colorectal liver metastases. Tech Vasc Interv Radiol. 2015;18(3):159–69.

19. Correa-Gallego C, Fong Y, Gonen M, D’Angelica MI, Allen PJ, DeMatteo RP, et al. A retrospective comparison of microwave ablation vs radiofrequency ablation for colorectal cancer hepatic metastases. Ann Surg Oncol. 2014;21(13):4278–83.

20. van der Pool AE, Mendez Romero A, Wunderink W, Heijmen BJ, Levendag PC, Verhoef C, et al. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg. 2010;97(3):377–82.

21. Dijkstra M, Nieuwenhuizen S, Puijk RS, Geboers B, Timmer FEF, Schouten EAC, et al. The role of neoadjuvant chemotherapy in repeat local treatment of recurrent colorectal liver metastases: a systematic review and meta-analysis. Cancers. 2021;13(3):378.

22. Dijkstra M, Nieuwenhuizen S, Puijk RS, Timmer FEF, Geboers B, Schouten EAC, et al. Improved survival in metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210(5):744-52, 52-5.

23. Dijkstra M, Nieuwenhuizen S, Puijk RS, Timmer FEF, Geboers B, Schouten EAC, et al. Local treatment of unresectable colorectal liver metastases: the role of neoadjuvant chemotherapy: an Amsterdam Colorectal Liver Met Registry (AmCORE) based study. Cancers. 2021;13(11).

24. Dijkstra M, Nieuwenhuizen S, Puijk RS, Timmer FEF, Geboers B, Schouten EAC, et al. Repeat local treatment of recurrent colorectal liver metastases, the role of neoadjuvant chemotherapy: an Amsterdam Colorectal Liver Met Registry (AmCORE) based study. Cancers (Basel). 2021;13(19).

25. Ruers T, Van Coevorden F, Punt C, Pieje JE, Borel-Rinkes I, Ledermann JA, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst. 2017;109(9).

26. Puijk RS, Ruarius AH, Vroomen L, van Tilborg A, Scheffer HJ, Nielsen K, et al. Colorectal liver metastases: surgery versus thermal ablation (COLLISSION) - a phase III single-blind prospective randomized controlled trial. BMC Cancer. 2018;18(1):821.

27. Nielsen K, van Tilborg AA, Meijerink MR, Macintosh MO, Zonderhuis BM, de Lange ES, et al. Incidence and treatment of local site recurrences following RFA of colorectal liver metastases. World J Surg. 2013;37(6):1340–7.

28. van Tilborg AA, Scheffer HJ, de Jong MC, Vroomen LG, Nielsen K, van Kuijk C, et al. MWA versus RFA for perivascular and peribiliary CRLM: a retrospective patient- and lesion-based analysis of two historical cohorts. Cardiovasc Interv Radiol. 2016;39(10):1438–46.

29. Tanis E, Nordlinger B, Mauer M, Sorbye H, van Coevorden F, Gruenenberger T, et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer. 2014;50(5):912–9.

30. Solbiati L, Livraghi T, Goldberg SN, Ierase T, Meloni F, Delanoce M, et al. Percutaneous radio-frequency ablation of hepatic
metastases from colorectal cancer: long-term results in 117 patients. Radiology. 2001;221(1):159–66.
31. Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol. 2008;15(10):2757–64.
32. Van Tilborg AA, Meijerink MR, Sietse C, Van Waesberge JH, Mackintosh MO, Meijer S, et al. Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. Br J Radiol. 2011;84(1002):556–65.
33. Ayav A, Germain A, Marchal F, Tierrius I, Laurent V, Bazin C, et al. Radiofrequency ablation of unresectable liver tumors: factors associated with incomplete ablation or local recurrence. Am J Surg. 2010;200(4):435–9.
34. Mahadevan A, Blanck O, Lanciano R, Peddada A, Sundararaman S, D’Ambrosio D, et al. Stereotactic body radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch(R) Patient Registry. Radiat Oncol. 2018;13(1):26.
35. Scorsetti M, Comito T, Tozzi A, Navarria P, Fogliata A, Clerici E, et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2015;141(3):543–53.
36. Berber B, Ibarra R, Snyder L, Yao M, Fabien J, Milano MT, et al. Multicentre results of stereotactic body radiotherapy for secondary liver tumours. HPB (Oxford). 2013;15(11):851–7.
37. Mendez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase II–II study. Acta Oncol. 2006;45(7):831–7.
38. Mendez Romero A, de Man RA. Stereotactic body radiation therapy for primary and metastatic liver tumors: from technological evolution to improved patient care. Best Pract Res Clin Gastroenterol. 2016;30(4):603–16.
39. Geboers B, Ruarus AH, Nieuwenhuizen S, Puijk RS, Scheffer HJ, de Grujil TD, et al. Needle-guided ablation of locally advanced pancreatic cancer: cytoreduction or immunomodulation as the endpoint in vivo vaccination? Chin Clin Oncol. 2019.
40. Ruarus AH, Vroomen L, Puijk RS, Scheffer HJ, Zonderhuis BM, Kazemier G, et al. Irreversible electroporation in hepatopancreatobiliary tumours. Can Assoc Radiol J. 2018;69(1):38–50.
41. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-34.
42. Puijk RS, Ahmed M, Adam A, Aray Y, Arellano R, de Baere T, et al. Consensus guidelines for the definition of time-to-event end points in image-guided tumor ablation: results of the SIO and DATECAN initiative. Radiology. 2021;301(3):533–40.
43. Bale R, Widmann G, Schullian P, Haidu M, Pald G, Klaus A, et al. Percutaneous stereotactic radiofrequency ablation of colorectal liver metastases. Eur Radiol. 2012;22(4):930–7.
44. Eng OS, Tsang AT, Moore D, Chen C, Narayanan S, Gannon CJ, et al. Outcomes of microwave ablation for colorectal cancer liver metastases: a single center experience. J Surg Oncol. 2015;111(4):410–3.
45. Gwak JH, Oh BY, Lee RA, Chung SS, Kim KH. Clinical applications of radio-frequency ablation in liver metastasis of colorectal cancer. J Korean Soc Coloproctol. 2011;27(4):202–10.
46. Hamada A, Yamakado K, Nakatsuka A, Uraki J, Kashima M, Takaki H, et al. Radiofrequency ablation for colorectal liver metastases: prognostic factors in non-surgical candidates. Jpn J Radiol. 2012;30(7):567–74.
47. Jiang BB, Yan K, Zhang ZY, Yang W, Wu W, Yin SS, et al. The value of KRAS gene status in predicting local tumor progression of colorectal liver metastases following radiofrequency ablation. Int J Hyperthermia. 2019;36(1):211–9.
48. Kennedy TJ, Cassera MA, Khajanee AS, Diwan TS, Hammill CW, Hansen PD. Laparoscopic radiofrequency ablation for the management of colorectal liver metastases: 10-year experience. J Surg Oncol. 2013;107(4):324–8.
49. Kim KH, Yoon YS, Yu CS, Kim TW, Kim HJ, Kim PN, et al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases. J Korean Surg Soc. 2011;81(1):25–34.
50. Liu M, Huang GL, Xu M, Pan FS, Lu MD, Zheng KG, et al. Percutaneous thermal ablation for the treatment of colorectal liver metastases and hepatocellular carcinoma: a comparison of local therapeutic efficacy. Int J Hyperthermia. 2017;33(4):446–53.
51. Mao R, Zhao JJ, Bi XY, Zhang YF, Han Y, Li ZY, et al. Resective recurrent colorectal liver metastasis: can radiofrequency ablation replace repeated metastasectomy? ANZ J Surg. 2019;89(7–8):908–13.
52. Qin S, Liu GJ, Huang M, Huang J, Luo Y, Wen Y, et al. The local efficacy and influencing factors of ultrasound-guided percutaneous microwave ablation in colorectal liver metastases: a review of a 4-year experience at a single center. Int J Hyperthermia. 2019;36(1):36–43.
53. Shady W, Petre EN, Gonen M, Erinjeri JP, Brown KT, Covey AM, et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes—a 10-year experience at a single center. Radiology. 2016;278(2):601–11.
54. Shi Y, Wang Z, Chl I, Shi D, Wang T, Cui D, et al. Long-term results of percutaneous microwave ablation for colorectal liver metastases. HPB (Oxford). 2020.
55. Takahashi H, Kahramangul B, Kose E, Berber E. A comparison of microwave thermosphere versus radiofrequency thermal ablation in the treatment of colorectal liver metastases. HPB (Oxford). 2018.
56. Valls C, Ramos E, Leiva D, Ruiz S, Martinez L, Rafecas A. Safety and efficacy of ultrasound-guided radiofrequency ablation of recurrent colorectal cancer liver metastases after hepatectomy. Scand J Surg. 2015;104(3):169–75.
57. Veltri A, Guarneri T, Gazzera C, Busso M, Solito F, Fora G, et al. Long-term outcome of radiofrequency thermal ablation (RFA) of liver metastases from colorectal cancer (CRC): size as the leading prognostic factor for survival. Radiol Med. 2012;117(7–8):1139–43.
58. Wang CZ, Yan GX, Xin H, Liu ZY. Oncological outcomes and predictors of radiofrequency ablation of colorectal cancer liver metastases. World J Gastrointest Oncol. 2020;12(9):1044–55.
59. Wang Y, Zhang GY, Xu LC, He XH, Huang HZ, Li GD, et al. Clinical outcomes and predictors in patients with unresectable colorectal cancer liver metastases following salvage percutaneous radiofrequency ablation: a single center preliminary experience. Technol Cancer Res Treat. 2020;19:1533033820963662.
60. Zhang K, Yu J, Zhou F, Yu X, Li X, Wang J, et al. Impact of timing and cycles of systemic chemotherapy on survival outcome of colorectal liver metastases patients treated by percutaneous microwave ablation. Int J Hyperthermia. 2016;32(5):531–8.
61. Erten O, Li P, Gokceimam M, Akbulut S, Berber E. Impact of ablation algorithm versus tumor-dependent parameters on local control after microwave ablation of malignant liver tumors. J Surg Oncol. 2020.
62. Fan Y, Zhu X, Lan Q, Lou F, Zheng Y, Lou H, et al. Thermal radiofrequency ablation as an adjuvant therapy for patients with colorectal liver metastasis. Oncol Res. 2016;23(5):219–28.
63. Doi H, Uemoto K, Suzuki O, Yamada K, Masai N, Tatsumi D, et al. Effect of primary tumor location and tumor size on the
response to radiotherapy for liver metastases from colorectal cancer. Oncol Lett. 2017;14(1):453–60.
64. Joo JH, Park JH, Kim JC, Yu CS, Lim SB, Park JJ, et al. Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer. Int J Radiat Oncol Biol Phys. 2017;99(4):876–83.
65. Fruhling P, Nilsson A, Duraj F, Haglund U, Noren A. Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: short to mid-term results. Eur J Surg Oncol. 2017;43(4):751–7.
66. Franzese C, Comito T, Clerici E, Di Brina L, Tomatis S, Navarra P, et al. Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation. J Cancer Res Clin Oncol. 2018.
67. Nieuwenhuizen S, Dijkstra M, Puijk RS, Timmer FEF, Nota IM, Opperman J, et al. Thermal ablation versus stereotactic ablative body radiotherapy to treat unresectable colorectal liver metastases: a comparative analysis from the prospective Amsterdam CORE registry. Cancers. 2021; 13(17).
68. Scheffer HJ, Vroomen LG, Nielsen K, van Tilborg AA, Comans EF, van Kuijk C, et al. Colorectal liver metastatic disease: efficacy of irreversible electroporation—a single-arm phase II clinical trial (COLDFIRE-2 trial). BMC Cancer. 2015;15:772.
69. ECIO. Ablation of colorectal liver metastases by irreversible electroporation: final results of the COLDFIRE-2 trial page 152019 [Available from: https://cslide.citmeetingtech.com/global_storage/media/content/ecio2019/ECIO_2019_Abstracts_and_Author_INDEX.pdf]. Accessed November 14, 2019.
70. Belgian health care knowledge center (K.C.E.) National Clinical Practice Guidelines of the College of Oncology: clinical practice guideline for colorectal cancer. 2006.
71. National Institute for Health and Care Excellence (N.I.C.E.) Radiofrequency ablation for colorectal liver metastases 2009 [Available from: https://www.nice.org.uk/guidance/IPG327]. Accessed 04–12–2019.
72. National Institute for Health and Care Excellence (N.I.C.E.) Microwave ablation for treating liver metastases 2016 [Available from: https://www.nice.org.uk/guidance/IPG555]. Accessed 04–12–2019.
73. National Institute for Health and Care Excellence (N.I.C.E.) Irreversible electroporation for treating liver metastases 2013 [Available from: https://www.nice.org.uk/guidance/IPG445]. Accessed 04–12–2019.
74. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422.
75. Gomez-Espana MA, Gallego J, Gonzalez-Flores E, Maurel J, Paez D, Sastre J, et al. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). Clin Transl Oncol. 2019;21(1):46–54.
76. Integraal Kankercentrum Nederland (I.K.N.L.) Guideline Colorectal Carcinoma 2019 [Available from: https://www.oncoline.nl/colorectaalcarcinoom. Accessed 04–12–2019.
77. Cancer Care Ontario (C.C.O.) The role of liver resection in colorectal cancer metastases 2012 [Available from: https://www.cancercareontario.ca/en/content/liver-resection-colorectal-metastases. Accessed 04–12–2019.
78. Herman J, Messersmith W, Suh WW, Blackstock W, Cosman BC, Mohiuddin M, et al. ACR Appropriateness criteria: rectal cancer-metastatic disease at presentation. Curr Probl Cancer. 2010;34(3):201–10.
79. Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al. Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2019.
80. Scottish Intercollegiate Guidelines Network (S.I.G.N.) Diagnosis and management of colorectal cancer 2016 [Available from: https://www.sign.ac.uk/assets/sign126.pdf]. Accessed 04–12–2019.
81. Phelip JM, Tougeron D, Leonard D, Benham L, Desolneux G, Dupre A, et al. Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCFD, SFED, SFRO, SFR). Dig Liver Dis. 2019;51(10):1357–63.
82. Bale R, Schullian P, Eberle G, Putzer D, Zoller H, Schneeberger S, et al. Stereotactic radiofrequency ablation of hepatocellular carcinoma: a histopathological study in explanted livers. Hepatology. 2019;70(3):840–50.
83. Widmann G, Schullian P, Haidu M, Bale R. Stereotactic radiofrequency ablation (SRFA) of liver lesions: technique effectiveness, safety, and interoperator performance. Cardiovasc Intervent Radiol. 2012;35(3):570–80.
84. Yu J, Liang P, Yu X, Liu F, Chen L, Wang Y. A comparison of microwave ablation and bipolar radiofrequency ablation both with an internally cooled probe: results in ex vivo and in vivo porcine livers. Eur J Radiol. 2011;79(1):124–30.
85. Yu NC, Raman SS, Kim YJ, Lassman C, Chang X, Lu DS. Microwave liver ablation: influence of hepatic vein size on heat-sink effect in a porcine model. J Vasc Interv Radiol. 2008;19(7):1087–92.
86. Facciorusso A, Di Maso M, Muscatello N. Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia. 2016;32(3):339–44.
87. Liu Y, Li S, Wan X, Li Y, Li B, Zhang Y, et al. Efficacy and safety of thermal ablation in patients with liver metastases. Eur J Gastroenterol Hepatol. 2013;25(4):442–6.
88. Franzese C, Comito T, Toska E, Tozzi A, Clerici E, De Rose F, et al. Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. Radiat Oncol. 2019;13:220–6.
89. He X, Zhang P, Li Z, Bi F, Xu F, Wang X, et al. Curative-intent radiotherapy in patients with oligometastatic lesions from colorectal cancer: a single-center study. Medicine (Baltimore). 2018;97(40):e12601.
90. Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27(10):1585–91.
91. Andratschke N, Alheid H, Allgauer M, Becker G, Blanch O, Boda-Heggemann J, et al. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer. 2018;18(1):283.
92. Comito T, Cozzi L, Clerici E, Campisi MC, Liardo RL, Navarra P, et al. Stereotactic ablative radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer. 2014;14:619.
93. Klement RJ, Abbas-Senger N, Adebahr S, Alheid H, Allgauer M, Becker G, et al. The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. BMC Cancer. 2019;19(1):173.
94. Merrell KW, Johnson JE, Mou B, Barney BM, Nelson KE, Mayo CS, et al. Stereotactic body radiotherapy for primary and metastatic liver tumors - the Mayo Clinic experience. J Radiosurg SBRT. 2016;4(2):133–44.
95. Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83(3):878–86.
96. Ahmed KA, Caudell JJ, El-Haddad G, Berglund AE, Welsh EA, Yue B, et al. Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2016;95(5):1399–404.
97. Mendez Romero A, Keskin-Cambay F, van Os RM, Nuyttens JJ, Heijmen BJM, IJzermans JNM, et al. Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy. Rep Pract Oncol Radiother. 2017;22(2):126–31.
98. Stintzing S, Grothe A, Hendrich S, Hoffmann RT, Heinemann V, Rentsch M, et al. Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases. Acta Oncol. 2013;52(5):971–7.
99. Jackson WC, Tao Y, Mendiratta-Lala M, Bazzi L, Wahl DR, Schipper MJ, et al. Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases. Int J Radiat Oncol Biol Phys. 2018;100(4):950–8.
100. Lahat E, Eshkenazy R, Zendai A, Zakai BB, Maor M, Dreznik Y, et al. Complications after percutaneous ablation of liver tumors: a systematic review. Hepatobiliary Surg Nutr. 2014;3(5):317–23.
101. Petrelli F, Comito T, Barni S, Pancera G, Scorsetti M, Ghidini A, et al. Stereotactic body radiotherapy for colorectal cancer liver metastases: a systematic review. Radiother Oncol. 2018.
102. Vroomen L, Petre EN, Cornelis FH, Solomon SB, Srimathveeravalli G. Irreversible electroporation and thermal ablation of tumors in the liver, lung, kidney and bone: what are the differences? Diagn Interv Imaging. 2017;98(9):609–17.
103. Nieuwenhuizen S, Puijk RS, van den Bemd B, Aldrighetti L, Arntz M, van den Boezem PB, et al. Resectability and ablatability criteria for the treatment of liver only colorectal metastases: multidisciplinary consensus document from the COLLISION trial group. Cancers (Basel). 2020; 12(7).

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.